Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$17,500.00
The Cholinergic System and Cognitive Impairments in Schizophrenia
EF 2020-21
Résumé
Schizophrenia affects about 1% of Canadians. Cognitive impairments are a core feature of schizophrenia that drives functional disability and socio-economic burden in this illness. Currently, there are no medications that improve cognition in schizophrenia. A better understanding of the neurobiology of these cognitive deficits could guide the development of new pharmacological treatments. The cholinergic system of the brain is important for cognitive abilities and it has been proposed that dysfunctions in this system would cause cognitive deficits in schizophrenia. However, this has not been tested yet. Here, we propose to study the cholinergic system with a positron emission tomography tracer that allows to quantify cholinergic innervation in the brain. The aims of the proposed study are to (1) establish whether individuals with schizophrenia show reduced cholinergic innervation compared to healthy individuals; (2) determine if reduced cholinergic innervation is related to general cognitive dysfunction, (3) brain activation and working memory in this illness. We hypothesize that, in schizophrenia, (1) cholinergic innervation is lower, (2) that this is related to greater general cognitive dysfunction and (3) to suboptimal brain activity and working memory. We will also explore the effect of biological sex on cholinergic innervation. We will inform patients and family, clinicians, and pharmaceutical firms of our findings to have them translated into clinical practice. As there are no drugs that alleviate cognitive impairments in schizophrenia, it is imperative to better understand the underlying neurobiology. This project will increase our understanding of the cholinergic system in schizophrenia and opens doors for breakthroughs in the development of new treatments.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
449590
Name
Saint-Georges Zacharie
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The Cholinergic System and Cognitive Impairments in Schizophrenia
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cholinergic System; Cognitive Impairments; Feobv; Functional Magnetic Resonance Imaging; N-Back Task; Positron Emission Tomography; Schizophrenia; Vesicular Acetylcholine Transporter; Working Memory
Abstract
Schizophrenia affects about 1% of Canadians. Cognitive impairments are a core feature of schizophrenia that drives functional disability and socio-economic burden in this illness. Currently, there are no medications that improve cognition in schizophrenia. A better understanding of the neurobiology of these cognitive deficits could guide the development of new pharmacological treatments. The cholinergic system of the brain is important for cognitive abilities and it has been proposed that dysfunctions in this system would cause cognitive deficits in schizophrenia. However, this has not been tested yet. Here, we propose to study the cholinergic system with a positron emission tomography tracer that allows to quantify cholinergic innervation in the brain. The aims of the proposed study are to (1) establish whether individuals with schizophrenia show reduced cholinergic innervation compared to healthy individuals; (2) determine if reduced cholinergic innervation is related to general cognitive dysfunction, (3) brain activation and working memory in this illness. We hypothesize that, in schizophrenia, (1) cholinergic innervation is lower, (2) that this is related to greater general cognitive dysfunction and (3) to suboptimal brain activity and working memory. We will also explore the effect of biological sex on cholinergic innervation. We will inform patients and family, clinicians, and pharmaceutical firms of our findings to have them translated into clinical practice. As there are no drugs that alleviate cognitive impairments in schizophrenia, it is imperative to better understand the underlying neurobiology. This project will increase our understanding of the cholinergic system in schizophrenia and opens doors for breakthroughs in the development of new treatments.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Saint-Georges, Zacharie
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~